-
Product Insights
NewNon Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2024
Empower your strategies with our Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – Drugs In Development, 2024 report and make more profitable business decisions. Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Most people with NAFLD experience no signs and symptoms and no complications, but in some people with the disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are...
-
Sector Analysis
Americas Alcoholic Beverages Sport Sponsorship Landscape – Biggest Brands and Spenders, Venue Rights, Deals, Trends and Case Studies
Americas Alcoholic Beverages Sports Sponsorship Landscape Overview Professional sports teams are the main recipients of the alcoholic beverage sector’s sponsorship deals. Alcoholic beverages are responsible for a few of the biggest sponsorship deals across the Americas with many highly recognized federations, events, and teams, including a few of the most profitable sports leagues in the world. The Americas alcoholic beverages sports sponsorship landscape report provides deep insights into the Americas alcoholic beverages sector sponsorship market trend, most active sport, and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Primary Biliary Cholangitis (Primary Biliary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Liver Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Liver Diseases report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Liver Diseases Drug Details: Saroglitazar (lipaglyn) is the first...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Primary Sclerosing Cholangitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Primary Sclerosing Cholangitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Primary Sclerosing Cholangitis Drug Details: Saroglitazar (lipaglyn) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Cholestasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Cholestasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Cholestasis Drug Details: Saroglitazar (lipaglyn) is the first Glitazar having...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Saroglitazar...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saroglitazar in Metabolic Dysfunction-Associated Steatotic Liver Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Epeleuton in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Epeleuton in Sickle Cell Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Epeleuton in Sickle Cell Disease Drug Details: Epeleuton (AF-102) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tazarotene in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazarotene in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazarotene in Idiopathic Pulmonary Fibrosis Drug Details: GRI-0621 is under...